Searchable abstracts of presentations at key conferences in oncology

oa0001p033 | (1) | PacRim7

LobSig, a prognostic signature for ILC

Reed Amy E McCart , Lal Samir , Nones Katia , Kutasovic Jamie R , Coorey Craig P , de Croft Priyakshi Kalita , Dalley Andrew , Kuo Luyu , Wockner Leesa , Robertson Alan , Ferguson Kaltin , Niland Colleen , Sachchithananthan Mythily , Vargas Ana Cristina , Miller Gregory , Black Debra , Johnson Julie , Reid Lynne E , Males Renique , Gresshoff Irma , Porter Alan , Evans Elizabeth , Saunus Jodi M , Al-Ejeh Fares , Pearson John V , Chenevix-Trench Georgia , Coin Lachlan , Waddell Nicola , Lakhani Sunil R , Simpson Peter T

Invasive lobular carcinoma (ILC) is the most common special type of breast cancer, and is characterized by functional loss of E-cadherin, resulting in cellular adhesion defects. ILC typically present as estrogen receptor positive, grade 2 breast cancers, with a good short-term prognosis. Several large-scale molecular profiling studies have now dissected the unique genomics of ILC. We have undertaken an integrative analysis of gene expression and DNA copy number to identify nov...

oa0001p008 | (1) | PacRim7

Mechanisms underlying uncontrolled genome doubling in breast cancer

Lee Christine S , Rogers Samuel , Fernandez Kristine , Alexandrou Sarah , Deng Niantao , Sergio C Marcelo , Kulkarni Abhijit , Gugasyan Lucy , Musgrove Elizabeth A , Deans Andrew J , Burgess Andrew , Caldon C Elizabeth

Uncontrolled genome doubling is an underlying cause of cancer cell aneuploidy and genomic instability, but relatively few drivers have been identified for this process. Cyclin E1 and cyclin E2 are cell cycle regulators whose dysregulation in oncogenesis promotes both increased proliferation and genomic instability. Due to their roles in normal physiological endoreduplication of the genome for specialised cell types, we hypothesised that cyclin E1 and cyclin E2 may be drivers o...

oa0001p001 | (1) | PacRim7

S phase dysregulation occurs following resistance to CDK4/6 inhibition ER+ breast cancer

Alexandrou Sarah , Milioli Heloisa Helena , Portman Neil , Lee Christine , Fernandez Kristine , Blake David , Lim Elgene , Caldon C Elizabeth

Endocrine resistant estrogen receptor positive (ER+) breast cancers are dependent upon cyclin-dependent kinases (CDK) 4/6 for proliferation, making them highly suitable for CDK4/6 inhibitor treatment. Despite initial efficacy, acquired resistance to CDK4/6 inhibitors is emerging and is now a major consideration in pre-clinical and clinical drug development. Current models of CDK4/6 inhibitor resistance do not mimic the clinical scenario where CDK4/6 inhibition will occur in th...

oa0001p043 | (1) | PacRim7

Activation of p53 in combination with endocrine and CDK targeted therapies in ER+ breast cancer

Portman Neil , Milioli Heloisa , Yong Aliza , Coulson Rhiannon , Alexandrou Sarah , Lam Natasha , Haupt Sue , Haupt Ygal , Caldon C Elizabeth , Lim Elgene

Estrogen Receptor (ER) signalling, upregulation of the cyclin/CDK pathway, and suppression of p53 form a critical axis controlling proliferation of ER positive breast cancer. In this setting, mutation of p53 is relatively rare and suppression of p53 function can be achieved via regulators MDM2 and MDMX. Activation of p53 by inhibition of MDM2 is a promising therapeutic target in p53 wildtype tumours and several drugs are currently in clinical trials. We hypothesised that the M...

oa0001p036 | (1) | PacRim7

Lipid elongation in prostate cancer: an androgen regulated process and a novel therapeutic target

Nassar Zeyad D , Centenera Margaret M , Machiels Jelle , Zinonos Irene , Hanson Adrienne , Bloch Katarzyna , Mah Chui Yan , Ryan Natalie K , Williams Elizabeth D , Evdokiou Andreas , Tilley Wayne D , Selth Luke A , Butler Lisa M , Swinnen Johannes V

Objective: Although initially effective, androgen deprivation therapy fails to achieve an enduring remission in patients with advanced prostate cancer (PCa) and the cells maintain active androgen receptor (AR) signalling. Hence, a detailed understanding of the AR-driven downstream processes that are required for tumour cell growth and survival, such as lipid metabolism, is essential to reveal new therapeutic targets. In this study, we aimed to evaluate the effect of androgens ...